Carboplatin: 338 Real Stories

338 stories match carboplatin. 332 of them mention chemotherapy.

A patient, who was diagnosed with Ovarian CancerOvarian Cancer

Ovarian Granulosa Cell Tumor Recurring 17 Years After Surgery

Patient Info: Anonymized, Female, 70+

Biomarkers: Weak oestrogen sensitivity

Complete resection was not possible, but debulking relieved pressure on surrounding structures and improved her quality of life. She then continued oncology care with palliative carboplatin and paclitaxel.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Ovarian CancerOvarian Cancer

Metastatic Clear Cell Ovarian Cancer Complicated by Treatment-Related Sarcoidosis

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Metastatic Site: peritoneum

During a treatment holiday, biopsy and laboratory evaluation showed treatment-related sarcoidosis rather than ovarian-cancer spread in the enlarged lymph nodes. After prednisone, the sarcoidosis resolved and imaging showed no progression of the clear cell ovarian cancer; she remained clinically well 4 months later.

PubMed Central
OutcomeStable Disease
A patient, who was diagnosed with Stage IV Ovarian CancerOvarian Cancer

Stage 4 Ovarian Cancer Discovered During Trigeminal Neuralgia Evaluation

Patient Info: Anonymized, Female, 50s | Stage IV

Three months after surgery, she had recovered well from debulking and 6 total chemotherapy cycles, with complete macroscopic clearance achieved at surgery. Trigeminal-neuralgia symptoms persisted and continued to require daily medication.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

Chemotherapy, immunotherapy, and surgery for lung cancer that spread to the foot

Patient Info: Anonymized, Female, 70+

Biomarkers: PD-L1 20%; no actionable mutations on next-generation sequencing.

She had a significant response after four cycles of chemotherapy and pembrolizumab, and the resected lung nodule contained fibrosis and scar without carcinoma; further systemic treatment and radiation were under consideration.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Gastric AdenocarcinomaGastric Cancer

Metastatic Gastric Cancer Causing Severe Hormone-Related Complications

Patient Info: Anonymized, Male, 70+ | Stage Metastatic/Advanced

Biomarkers: HER2 negative; Ki-67 70%; CD56 positive; synaptophysin positive; weak chromogranin expression; ectopic ACTH secretion; elevated serum chromogranin A

Metastatic Site: liver

His liver metastases enlarged despite carboplatin, and his weight loss, appetite, and mobility worsened. He received palliative care during a later admission and died a few days afterward.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage III Lung CancerLung Cancer

Strong Response to Pembrolizumab-Based Therapy for Pleomorphic Lung Cancer

Patient Info: Anonymized, Male, 60s | Stage III

Biomarkers: EGFR-negative; ALK-negative; ROS1-negative; PD-L1 TPS 90%-100%.

A marked response followed four combination cycles, and maintenance pembrolizumab remained ongoing seven months after treatment began.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung CancerLung Cancer

Pembrolizumab Controlled Metastatic Pleomorphic Lung Cancer After Chemotherapy Failed

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: EGFR-negative; ALK-negative; ROS1-negative; BRAF-negative; PD-L1 TPS 60%-70%; BRCA2, and TP53 mutations; tumor mutation burden 42 mutations/Mb; no actionable alteration.

Metastatic Site: right adrenal gland; left adrenal gland; bone

Tumor diameter had decreased at 11 months, and pembrolizumab remained ongoing at 12 months.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Lung Squamous Cell CarcinomaLung Cancer

Lung Cancer Metastases to Both Kidneys Causing Kidney Failure

Patient Info: Anonymized, Male, 50s | Stage Metastatic/Advanced

Biomarkers: PD-L1 highly expressed

Metastatic Site: brain|bilateral kidneys|lungs

The cancer progressed in both kidneys and lungs despite treatment, causing dialysis-dependent kidney failure. He later developed severe respiratory illness and died 5 days after readmission.

PubMed Central
OutcomeIn Memory
SH
Lung Cancer

Severe headache during chemotherapy for small-cell lung cancer

Patient Info: Anonymized, Male, 50s

After the regimen change, he completed five chemotherapy cycles, remained free of severe headache, and had improvement in chest pain, cough, and breathing.

PubMed Central
OutcomeResponding Well
AP
Lung Cancer

A painful scalp metastasis from sarcomatoid lung cancer

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: No targetable mutations identified; CAM5.2-positive; p63-positive; CD10-positive; vimentin-positive.

Metastatic Site: chest wall and rib; liver; right gluteal region; scalp…

Her disease progressed with a further liver lesion and additional metastatic complications, and systemic treatment was stopped because of severe immune-related toxicity and the absence of targetable mutations.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

Low-dose intrapleural therapy relieved a complex malignant pleural effusion

Patient Info: Anonymized, Female, Under 40 | Stage Metastatic/Advanced

Biomarkers: EGFR mutation-negative; ALK alteration-negative; ROS1 alteration-negative.

Metastatic Site: pleura; adrenal gland; bone

The lung cancer had progressed after initial chemotherapy, but rescue treatment of the infected loculated pleural effusion drained 2,000 mL, resolved the collection, and improved her breathing and fever.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Ovarian AdenocarcinomaOvarian Cancer

Kidney Complications After Treatment for Stage IV Ovarian Cancer

Patient Info: Anonymized, Female, 60s | Stage IV

Metastatic Site: peritoneum|left lymph node

No further ovarian-cancer progression was observed during the 10 months after kidney biopsy. The nephrotic syndrome reached partial remission after immunosuppressive treatment was stopped and supportive care continued.

PubMed Central
OutcomeStable Disease
A patient, who was diagnosed with Small Cell Lung CancerLung Cancer

Extensive-stage small cell lung cancer with acquired haemophilia

Patient Info: Anonymized, Female, 60s

Biomarkers: Synaptophysin weakly positive; Ki-67 greater than 90%.

Her small cell lung cancer remained stable on imaging one month before her death, which followed aseptic meningitis after intravenous immunoglobulin treatment for autoimmune myasthenia gravis.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

A regressed choroidal metastasis during EGFR-targeted lung cancer treatment

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: EGFR exon 19 deletion.

Metastatic Site: liver; bone; central nervous system; right choroid

The right choroidal metastasis appeared inactive and regressed during systemic treatment, visual acuity remained 20/20, and no local eye treatment was required.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

A durable response to trastuzumab in heavily pretreated metastatic breast cancer

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Initial tumor ER-positive and PR-positive. Metastatic liver biopsy ER-negative and PR-negative with HER2 IHC 1+ and nonamplified. Later biopsy ER and PR weakly positive at 5%–10%, HER2 IHC 1+ and nonamplified, and ERBB3 p. with evidence of HER2/HER3 pathway activation.

Metastatic Site: lungs; hilar and mediastinal lymph nodes; liver; bone

She had ongoing benefit for more than 10 months on trastuzumab and capecitabine, with improved symptoms, lower tumor markers, and a confirmed partial response.

PubMed Central
OutcomeResponding Well
Alexandra, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage III Breast Cancer: Alexandra's Patient Story

Patient Info: Alexandra, Female, 40s | Stage III

As of 2021, Alexandra was living with Stage III breast cancer and continuing chemotherapy after treatment with docetaxel, carboplatin, antibody drug conjugates, and tamoxifen.

Our Cancer Stories
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Metastatic Lung Cancer Responded Completely After a Change in Immunotherapy

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: TTF-1-positive; napsin-positive; PD-L1 0%; high tumour mutational burden; no actionable mutations

Metastatic Site: bone (left iliac bone, acetabulum and thoracic…

After progression on nivolumab, atezolizumab produced a complete response by the 6-month scan; after 35 cycles, the response remained sustained, he was alive and well, and no immune-related adverse effects were documented.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Small Cell Lung CancerLung Cancer

Small-Cell Lung Cancer First Appeared as Rapidly Worsening Nerve Damage

Patient Info: Anonymized, Female, 60s

Biomarkers: Anti-Hu-positive; anti-CV2/CRMP5-positive; anti-SOX1-positive

Despite six cycles of carboplatin and etoposide and intensive treatment for the paraneoplastic neuropathy, her neurological condition progressed; after a thrombocytopenia-related brain haemorrhage, she entered palliative care and died within weeks.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Recurrent Breast Cancer With a Benign-Appearing Chest-Wall Rash

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Initial tumor: ER-positive; PR-negative; HER2-negative.

Metastatic Site: mediastinal lymph nodes

She had recurrent chest-wall and mediastinal metastatic disease; a later rash biopsy showed dermatitis rather than another skin recurrence.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Ovarian CancerOvarian Cancer

Ovarian Fibrosarcoma Recurring Rapidly After Debulking Surgery

Patient Info: Anonymized, Female, 40s

Biomarkers: Ki-67 greater than 20%; vimentin diffusely positive; muscle-specific antigen weakly positive

The cancer recurred with a new pelvic mass and ascites 3 months after surgery. Her condition was too poor for chemotherapy, and she died on the second day of palliative hospital care.

PubMed Central
OutcomeIn Memory